78 related articles for article (PubMed ID: 18362148)
41. Cysteine cathepsins: from structure, function and regulation to new frontiers.
Turk V; Stoka V; Vasiljeva O; Renko M; Sun T; Turk B; Turk D
Biochim Biophys Acta; 2012 Jan; 1824(1):68-88. PubMed ID: 22024571
[TBL] [Abstract][Full Text] [Related]
42. The endosome-lysosome pathway and information generation in the immune system.
Watts C
Biochim Biophys Acta; 2012 Jan; 1824(1):14-21. PubMed ID: 21782984
[TBL] [Abstract][Full Text] [Related]
43. Specific functions of lysosomal proteases in endocytic and autophagic pathways.
Müller S; Dennemärker J; Reinheckel T
Biochim Biophys Acta; 2012 Jan; 1824(1):34-43. PubMed ID: 21767668
[TBL] [Abstract][Full Text] [Related]
44. The crystal structures of two salivary cystatins from the tick Ixodes scapularis and the effect of these inhibitors on the establishment of Borrelia burgdorferi infection in a murine model.
Kotsyfakis M; Horka H; Salat J; Andersen JF
Mol Microbiol; 2010 Jul; 77(2):456-70. PubMed ID: 20545851
[TBL] [Abstract][Full Text] [Related]
45. Human and mouse perforin are processed in part through cleavage by the lysosomal cysteine proteinase cathepsin L.
Konjar S; Sutton VR; Hoves S; Repnik U; Yagita H; Reinheckel T; Peters C; Turk V; Turk B; Trapani JA; Kopitar-Jerala N
Immunology; 2010 Oct; 131(2):257-67. PubMed ID: 20497254
[TBL] [Abstract][Full Text] [Related]
46. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S.
Guncar G; Pungercic G; Klemencic I; Turk V; Turk D
EMBO J; 1999 Feb; 18(4):793-803. PubMed ID: 10022822
[TBL] [Abstract][Full Text] [Related]
47. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.
Bevec T; Stoka V; Pungercic G; Dolenc I; Turk V
J Exp Med; 1996 Apr; 183(4):1331-8. PubMed ID: 8666891
[TBL] [Abstract][Full Text] [Related]
48. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain.
Fineschi B; Sakaguchi K; Appella E; Miller J
J Immunol; 1996 Oct; 157(8):3211-5. PubMed ID: 8871612
[TBL] [Abstract][Full Text] [Related]
49. Inhibitory p41 isoform of invariant chain and its potential target enzymes cathepsins L and H in distinct populations of macrophages in human lymph nodes.
Zavasnik-Bergant V; Schweiger A; Bevec T; Golouh R; Turk V; Kos J
Immunology; 2004 Jul; 112(3):378-85. PubMed ID: 15196205
[TBL] [Abstract][Full Text] [Related]
50. Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation.
Mihelic M; Dobersek A; Guncar G; Turk D
J Biol Chem; 2008 May; 283(21):14453-60. PubMed ID: 18362148
[TBL] [Abstract][Full Text] [Related]
51. The p41 fragment story.
Turk D; Guncar G; Turk V
IUBMB Life; 1999 Jul; 48(1):7-12. PubMed ID: 10791909
[TBL] [Abstract][Full Text] [Related]
52. Lysosomal cysteine proteases and antigen presentation.
Rudensky A; Beers C
Ernst Schering Res Found Workshop; 2006; (56):81-95. PubMed ID: 16329647
[TBL] [Abstract][Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
